Previous close | 75.10 |
Open | 75.46 |
Bid | 75.35 x 500 |
Ask | 75.41 x 500 |
Day's range | 74.99 - 75.62 |
52-week range | 64.02 - 87.88 |
Volume | |
Avg. volume | 1,788,249 |
Market cap | 17.694B |
Beta (5Y monthly) | 1.02 |
PE ratio (TTM) | 35.73 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Hologic's (HOLX) second-quarter fiscal 2024 performance is likely to be driven by the GYN Surgical portfolio.
Zacks.com users have recently been watching Hologic (HOLX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Strength in Molecular Diagnostics business and GYN Surgical is likely to have driven Hologic's (HOLX) fiscal second-quarter performance.